Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 10/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 6/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | FBP1 | P09467 | 1/20 | 0.55 |
| ▸ | DUSP26 | Q9BV47 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | CDC25A | P30304 | 1/20 | 0.50 |
| ▸ | CDC25B | P30305 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2304813 | 1.00 | RXFP1 (0.78) | RXFP1KDM4ENPSR1ALDH1A1POLB | |
| SCHEMBL189044 | 0.88 | RXFP1 (1.00) | RXFP1KDM4ENPSR1ALDH1A1POLB | |
| SCHEMBL189608 | 0.85 | ALDH1A1 (1.00) | RXFP1KDM4ENPSR1ALDH1A1POLB | |
| SCHEMBL2304390 | 0.84 | RXFP1 (0.76) | RXFP1KDM4ENPSR1ALDH1A1POLB | |
| SCHEMBL2307185 | 0.83 | RXFP1 (0.69) | RXFP1KDM4ENPSR1ALDH1A1POLB | |
| SCHEMBL2301817 | 0.82 | RXFP1 (0.67) | RXFP1KDM4ENPSR1ALDH1A1POLB | |
| SCHEMBL2301679 | 0.80 | RXFP1 (0.83) | RXFP1KDM4ENPSR1ALDH1A1POLB | |
| SCHEMBL2304587 | 0.80 | RXFP1 (0.76) | RXFP1KDM4ENPSR1ALDH1A1POLB | |
| SCHEMBL15180083 | 0.78 | RXFP1 (0.80) | RXFP1KDM4ENPSR1ALDH1A1POLB | |
| SCHEMBL2355912 | 0.78 | PIK3CD (0.70) | ALDH1A1POLBMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20110312960-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-22 | — | — | US | disclosed |
| US-8071597-B2 | Pyrazine compounds and uses as PI3K inhibitors | MERCK SERONO SA (CH) | 2011-12-06 | — | — | US | disclosed |
| CN-101296909-B | pyrazine derivatives and application thereof as PI3K inhibitor | SERONO LAB | 2011-10-12 | — | — | CN | disclosed |
| EP-2351745-A1 | Pyrazine derivatives and use as PI3K inhibitors | Merck Serono S.A. (CH) | 2011-08-03 | — | — | EP | disclosed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | disclosed |
| CN-101296909-A | Pyrazine derivatives and application thereof as PI3K inhibitor | SERONO LAB (CH) | 2008-10-29 | — | — | CN | disclosed |
| EP-1917252-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007023186-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | PI4KA, PIP5K1B, PDPK1 | RXFP1 4100/4885KDM4E 2673/4885NPSR1 3391/4885 |
| US-20110312960-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | PIK3R5, PIK3CD, PIK3CA | RXFP1 4342/4885KDM4E 4420/4885NPSR1 3788/4885 |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | PIK3R5, PIK3CD, PIK3CA | RXFP1 4342/4885KDM4E 4420/4885NPSR1 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.